Home・Aktien・Certara Inc

Certara Inc

Geschlossen

BrancheGesundheitswesen

8.07 -1.22

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

7.99

Max

8.18

Schlüsselkennzahlen
By Trading Economics
Einkommen	-2.9M -8.8M
Verkäufe	3.3M 107M
KGV Branchendurchschnitt	100.714 68.51
EPS	0.09
Gewinnspanne	-8.196
Angestellte	1,515
EBITDA	-16M 16M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+1.73% upside

Dividenden
By Acuity
Nächstes Ergebnis	5. Nov. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	474M 1.3B
Vorheriger Eröffnungskurs	9.29
Vorheriger Schlusskurs	8.07

Nachrichtenstimmung

By Acuity

50%

128 / 340 Ranking in Healthcare

Certara Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Certara Inc Prognose

Kursziel

By TipRanks

1.73% Vorteil

12-Monats-Prognose

Durchschnitt 8.21 USD 1.73%

Hoch 9 USD

Tief 7 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Certara Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

9 ratings

Buy

Halten

Sell

Basierend auf 9 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Certara Inc – Dist abgegeben haben.

Stimmung

By Acuity

128 / 340 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.